Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Surgical Prophylaxis Clear all
Completed Phase 4 Interventional

Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone

NCT05681182
View directory record Official record
Conditions
Post Operative Atrial Fibrillation
Interventions
CardiaMend with the Addition of Amiodarone
Combination Product
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
20 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

NCT00699946
View directory record Official record
Conditions
Delirium
Interventions
olanzapine, placebo
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
65 Years and older
Enrollment
495 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Jul 22, 2026, 4:57 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.

NCT03982810
View directory record Official record
Conditions
Surgical Site Infection, Antibiotic Prophylaxis
Interventions
Antibiotics
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Jul 22, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

NCT06451003
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Exposure to clinical decision support system and education
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Phase 3 Interventional

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery

NCT00460473
View directory record Official record
Conditions
Delirium
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
30
States / cities
Loma Linda, California • Los Angeles, California • Pasadena, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Jul 22, 2026, 4:57 PM EDT
Recruiting No phase listed Observational

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

NCT06888388
View directory record Official record
Conditions
Breast Cancer Surgery
Interventions
Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy
Procedure
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2Phase 3 Interventional

Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer

NCT00765479
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy protein isolate, placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)

NCT01507194
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Ondansetron, Vestipitant
Drug
Lead sponsor
Accenture
Industry
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
7
States / cities
Sheffield, Alabama • Phoenix, Arizona • Boynton Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)

NCT00692770
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Nexavar (Sorafenib, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Nitrofurantoin and Urinary Tract Infections (UTIs)

NCT00678041
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Nitrofurantoin, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection

NCT03915470
View directory record Official record
Conditions
Staphylococcal Infections, Surgical Site Infection
Interventions
XF-73, Placebo
Drug
Lead sponsor
Destiny Pharma Plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Gainesville, Florida • Pocatello, Idaho • Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Phase 3 Interventional

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

NCT00087256
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Celecoxib, placebo
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jul 22, 2026, 4:57 PM EDT
Not listed Not applicable Interventional

A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)

NCT02664168
View directory record Official record
Conditions
Surgical Wound Infection
Interventions
Aquacel Ag Surgical Dressing, Single-Use Negative Pressure Wound Therapy (PICO)
Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Jul 22, 2026, 4:57 PM EDT
No Longer Available No phase listed Expanded access

HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency

NCT01701947
View directory record Official record
Conditions
Wound; Rupture, Surgery, Cesarean Section, Postpartum Hemorrhage, Surgery
Interventions
Hemoleven
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
6 Months and older
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Not applicable Interventional Results available

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

NCT02255487
View directory record Official record
Conditions
Surgical Site Infection
Interventions
IrriSept System, No Intervention - Standard of Care (SoC) only
Device · Other
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

NCT03827655
View directory record Official record
Conditions
Postoperative Gastrointestinal Dysfunction
Interventions
TAK-954 Placebo, TAK-954
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jul 22, 2026, 4:57 PM EDT
Not listed Not applicable Interventional

A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO) or Standard Care Dressings (AQUACEL Ag SURGICAL Dressing).

NCT03180346
View directory record Official record
Conditions
Surgical Incision
Interventions
PICO, Aquacel
Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 22, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.

NCT07063979
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Bariatric Sleeve Gastrectomy
Interventions
Wearable Transcutaneous electrical Nerve Stimulation unit to mitigate postoperative nausea and vomiting (PONV) in the Bariatric Surgical Patient, A sham device that will mimic the active wearable device. It will look the same, and buzz but will not actually admit a low-leve electric current that would stimulate the nerves.
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Prevention of Broncho-aspiration (BA) in Adult Subjects During Their ICU Stay

NCT05284084
View directory record Official record
Conditions
Bronchial Aspiration
Interventions
Bed Head elevation, H2 blockers and mouth wash, Data collection for comparison
Other
Lead sponsor
Marshall University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 3 Interventional

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

NCT00049452
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Stamford, Connecticut • Paramus, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2 Interventional

Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients

NCT00600990
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
GW597599
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Little Rock, Arkansas • Glendale, California • Laguna Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jul 22, 2026, 4:57 PM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209
View directory record Official record
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 4:57 PM EDT
Completed Phase 2Phase 3 Interventional

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

NCT00902928
View directory record Official record
Conditions
Venous Thromboembolism, Arthroplasty, Replacement, Hip
Interventions
YM150, enoxaparin
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Jul 22, 2026, 4:57 PM EDT
Not yet recruiting Phase 1 Interventional

Psilocybin After Trauma Surgery for Pain

NCT07406828
View directory record Official record
Conditions
Pain Management, Postoperative Pain
Interventions
Psilocybin (Usona Institute), Postoperative analgesia
Drug
Lead sponsor
Trent Emerick
Other
Eligibility
25 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 4:57 PM EDT